RxDoctor Payments Data

Matthew Gatlin, PA

Physician Assistant · Superior, NENPI 1245552140

Payments from drug & device makers

$2,325in general payments, 2019–2025

Across 135 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$738
  • Astellas Pharma US Inc$364
  • Otsuka America Pharmaceutical, Inc.$326
  • Novo Nordisk$265
  • Amgen$264
  • Lilly USA, LLC$73
  • plus $295 from 11 others

What the payments were for

  • Food & beverage$1,99486%
  • Education$33114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,325 in reported general payments places this provider in the 85th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$15,496
Medicare patients
74
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$87,332
EliquisApixaban80$61,782
JardianceEmpagliflozin71$53,443
XareltoRivaroxaban38$20,175
LinzessLinaclotide15$11,661
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$10,227
FarxigaDapagliflozin Propanediol13$9,329
Synjardy XrEmpagliflozin/Metformin Hcl13$8,636
JanuviaSitagliptin Phosphate12$6,737
MyrbetriqMirabegron15$6,661
AbrysvoRsv Vacc, Pref A And Pref B/Pf20$6,472
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,836
Hysingla ErHydrocodone Bitartrate13$4,314
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,245
Fentanyl11$3,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$265$87,33282 claims
PfizerEliquis, Abrysvo$65$68,253100 claims
Johnson & JohnsonXarelto$26$20,17538 claims
AbbVieLinzess$738$11,66115 claims
Astellas Pharma US IncMyrbetriq$364$6,66115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Superior

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →